EU judges must clarify legal opinion on combination drugs and SPCs
This article was originally published in Scrip
Brian Cordery and Laura Reynolds argue that, while the Court of Justice for the European Union should adopt much of a recent opinion handed down on SPCs, refinements are needed in key areas to avoid confusion and injustice.
You may also be interested in...
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.
Germany’s family-owned Boehringer Ingelheim has supplemented its research efforts into finding COVID-19 therapies by supporting employees who volunteer to take part in COVID-19 relief efforts and by donating health care supplies, helped by a solid 2019 financial performance.